Abstract
In recent years, much attention has been focused on cyclosporin as a new alternative drug for the treatment of recalcitrant disabling psoriasis vulgaris. This drug has the important advantage of being non-myelotoxic as compared to other immunosuppressants. In conjunction with the earlier reported data concerning the clinical use of cyclosporin to treat severe psoriasis, three treatment schedules are outlined: short-term, intermittent and long-term. Uncontrolled treatment of psoriasis with cyclosporin could increase the risk of irreversible renal damage. The use of cyclosporin, therefore, requires a multidisciplinary ap proach in which regular consultations and monitoring by a dermatologist and, if warranted, by a nephrologist are imperative.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
